Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 12/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | UBE2N | P61088 | 1/20 | 0.41 |
| ▸ | FSCN1 | Q16658 | 3/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.37 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21557646 | 0.89 | MAPK1 (0.46) | MAPK1SMN1; SMN2LMNAHTTUBE2N | |
| SCHEMBL25970612 | 0.88 | MAPK1 (0.49) | MAPK1SMN1; SMN2HTTUBE2NFSCN1 | |
| SCHEMBL20504084 | 0.83 | ALDH1A1 (0.43) | MAPK1SMN1; SMN2LMNAHTTFSCN1 | |
| SCHEMBL25970882 | 0.82 | MAPK1 (0.70) | MAPK1 | |
| SCHEMBL25970877 | 0.82 | MAPK1 (0.70) | MAPK1 | |
| SCHEMBL25970826 | 0.80 | MAPK1 (0.71) | MAPK1 | |
| SCHEMBL25970859 | 0.80 | MAPK1 (0.71) | MAPK1 | |
| SCHEMBL25970871 | 0.80 | MAPK1 (0.71) | MAPK1 | |
| SCHEMBL25970764 | 0.80 | MAPK1 (0.71) | MAPK1SMN1; SMN2FSCN1 | |
| SCHEMBL25970830 | 0.80 | MAPK1 (0.71) | MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11708364-B2 | Azaindole derivatives and their use as ERK kinase inhibitors | AGV DISCOVERY (FR) | 2023-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11708364-B2 | Azaindole derivatives and their use as ERK kinase inhibitors | MAPKAPK2, MAPK1, MAPK3 | MAPK1 2/4885SMN1; SMN2 4252/4885LMNA 4418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.